Touchlight and GSK Sign License Agreement for Use of Enzymatic dbDNA Production Technology for mRNA Manufacturing
Touchlight announced a license agreement with GSK, a global leader in biopharmaceutical innovation.
July 24, 2024
by Biotech Newswire
Breakthroughs in Melanoma Immunotherapy & RNA Vaccines
Melanoma is a type of skin cancer that develops from pigment-producing cells called melanocytes.
July 3, 2023
by Daivd Orchard Webb/PharmaSources
First study to show waning effectiveness of 3rd dose of mRNA vaccines
A nationwide study from the U.S. Centers for Disease Control and Prevention (CDC) is the first to show that immunity against severe COVID-19 disease begins to wane 4 months after receipt of the third dose of an mRNA vaccine (Pfizer or Moderna).
February 14, 2022
by WorldPharmaNews
Johnson & Johnson's Covid-19 vaccine holds up in US durability study
Findings were unveiled Thursday from the largest US study to date on the durability of COVID-19 vaccines, with Johnson & Johnson's jab producing a robust result in terms...
January 7, 2022
by FirstWordPharma
Tonix and Kansas State University to develop mRNA vaccines for Covid-19
The ZNP technology could offer increased stability to mRNA vaccines at various temperatures.
January 6, 2022
by Pharmaceutical-Technology
Delaying second dose of mRNA COVID-19 vaccine produces stronger immune response
The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. The study is funded by the Government of Canada...
December 2, 2021
by WorldPharmaNews
Biotage expands production capacity to ease lipid bottlenecks
New site in Cardiff boosts the company's production capacity for equipment crucial in the supply chain for mRNA vaccines production
August 19, 2021
by cphi-online
Investigation of reports of myocarditis in connection with COVID-19 mRNA vaccines
Very rare reports received worldwide of myocarditis with a possible link to the use of mRNA vaccines against COVID-19 are currently under investigation.
June 7, 2021
by firstwordpharma
Precision NanoSystems joins Danaher's Life Sciences Platform
Precision NanoSystems (PNI) has been acquired by Danaher Corporation's Life Sciences platform. PNI is a global leader in technologies and solutions for the development of genetic medicines, including mRNA vaccines and therapeutics.
June 2, 2021
by firstwordpharma
Merck KGaA boosts lipid capacity to meet vaccine demand
The company's new synthetic cholesterol product will help meet the demand for mRNA vaccines, including Pfizer-BioNTech Covid-19 Vaccine
May 31, 2021
by cphi-online
Global Trial for COVID-19 Vaccine Begins at NYU Langone Health
The first U.S. patients are being dosed in a Phase 2/3 clinical trial testing whether a messenger RNA (mRNA) vaccine candidate can prevent infection with the virus that causes 2019 coronavirus disease (COVID-19).
August 4, 2020
by americanpharmaceuticalreview
European Investment Bank to provide BioNTech with up to €100 million in debt financing for COVID-19 vaccine development and manufacturing
mRNA vaccines consist of genetic material, called messenger RNA, that provides instructions for a human cell to make a target protein, or immunogen, which activates the body’s immune response against the respective virus.
June 12, 2020
by expresspharma